ADENOSINE AND RETINAL ISCHEMIA

腺苷和视网膜缺血

• 批准号: 2164155
• 负责人: STEVEN ROTH
• 金额: $ 26.96万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2164155
• 关键词: adenosine; blood flow measurement; cats; disease /disorder model; electroretinography; eye disorder chemotherapy; hypoxia; ischemia; nonhuman therapy evaluation; oxygen consumption; purinergic receptor; reperfusion; retina circulation; retina disorder; theophylline

Retinal ischemia occurs when the oxygen and glucose supply to the retina is interrupted. This condition may occur in retinal vascular diseases such as retinal artery occlusion, or as a result of systemic diseases such as diabetes mellitus. The pathophysiology of retinal injury following ischemia appears to involve excitatory amino acids and disturbances in blood flow. The local concentration of adenosine increases massively during cerebral ischemia, and exogenous adenosine analogues administered to animals before or after ischemia have produced ameliorative effects. An adenosine analogue has been found to attenuate retinal ischemic injury in rabbits, and adenosine appears to be one factor involved in the retinal vascular response to decreased blood oxygen content. The overall hypothesis of this study is that adenosine is a critical factor in the retinal response to conditions where oxygen and./or glucose delivery to the retina is diminished. Based upon this function of adenosine, the use of selective adenosine against, or modulation of endogenous adenosine concentration, may allow manipulation of critical events (excitatory amino acid concentration or blood flow alterations) during or after retinal ischemia. To evaluated the role of adenosine in retinal ischemia, adenosine concentration will be measured in the retina during hypoxic and ischemia. The use of adenosine antagonists under these conditions will allow evaluation of the influence of adenosine on blood flow in the retina. In another series of experiments, we will use selective adenosine agonists either before or after retinal ischemia to examine whether adenosine can provide an attenuation of retinal injury. These studies will provide new information on the role of adenosine in compensatory mechanisms during and after retinal ischemia and potential therapeutic approaches to prevent or ameliorate retinal ischemic injury and visual loss.

当氧气和葡萄糖向视网膜供应时，视网膜缺血发生 被打断了。 这种情况可能发生在视网膜血管疾病中 例如视网膜动脉阻塞或全身性疾病 例如糖尿病。 视网膜损伤的病理生理学 以下缺血似乎涉及兴奋性氨基酸和 血流的干扰。 腺苷的局部浓度 在脑缺血和外源性腺苷期间大量增加 缺血之前或之后给动物施用的类似物 改善效果。 已经发现腺苷类似物可以减弱 兔子的视网膜缺血性损伤，腺苷似乎是一种 视网膜血管反应减少血液的因素 氧含量。 这项研究的总体假设是腺苷 是对氧气的视网膜反应的关键因素 and./or葡萄糖向视网膜递送。 基于此 腺苷的功能，选择性腺苷反对或 内源性腺苷浓度的调节可能允许操纵 关键事件（兴奋性氨基酸浓度或血流 在视网膜缺血期间或之后的改变）。 评估 视网膜缺血中的腺苷，将测量腺苷浓度 在缺氧和缺血期间的视网膜中。 腺苷的使用 在这些条件下的拮抗剂将允许评估影响 视网膜中血流的腺苷的。 在另一个系列 实验，我们之前或 视网膜缺血后检查腺苷是否可以提供 视网膜损伤的衰减。 这些研究将提供新的 有关腺苷在补偿机制中的作用的信息 在视网膜缺血和潜在的治疗方法之后 预防或改善视网膜缺血性损伤和视觉丧失。